Why Semaglutide Works Differently in Some People
Quick Facts
Why do people respond so differently to semaglutide?
Semaglutide is a GLP-1 receptor agonist. In the pivotal STEP 1 trial, adults with obesity lost an average of about 15% of body weight over 68 weeks. An average hides a wide spread: some participants lost far more, and others lost little. Adherence, dose, diet, sex, baseline weight, medication side effects and biology all play a part.
A report in Nature Medicine adds a genetic explanation. It indicates that rare variants in GLP1R, the gene encoding the receptor semaglutide activates, are associated with a smaller weight-loss effect. Rare variants can change how well a receptor binds a drug or sends signals into the cell. If the receptor works less efficiently, a drug designed around it may do less. The size and clinical meaning of this effect need confirmation in further studies.
Why might tirzepatide be less affected by GLP1R variants?
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. In the SURMOUNT-1 trial, average weight loss at 72 weeks ranged from about 15% to about 21% depending on dose. A second hormonal pathway offers a plausible reason it could keep working when GLP-1 receptor signaling is reduced. Differences in how each molecule binds the receptor may also matter. The mechanism is still a hypothesis.
If confirmed, this would support precision prescribing, in which genetic information helps match patients to the drug most likely to work. That is not current practice. Variants of this kind are rare, so most people with a modest response to semaglutide do not carry one, and genetic testing is not part of guideline-based obesity care. For now the findings are best seen as insight into drug biology that could inform later trials.
What should patients and clinicians take from this?
Weight-loss medicines work best alongside nutrition, physical activity and long-term follow-up. If someone has taken an adequate dose for several months with little response, clinicians usually review adherence, dose escalation, other medicines and contributing conditions before considering a switch. Genetic differences are only one possible cause.
The work also reflects a shift toward understanding obesity as a heterogeneous disease with varied biology. Future research may combine genetic, metabolic and behavioral data to predict who responds to which drug. Until then, prescribing relies on clinical judgment, patient preference, tolerability, cost and access.
Frequently Asked Questions
No. Current guidelines do not recommend genetic testing before prescribing GLP-1 medicines. The variants described are rare, and the research is still preliminary.
Not necessarily. Tirzepatide produced larger average weight loss than semaglutide in clinical trials, but individual results vary. A clinician can review whether a switch is appropriate.
The variants highlighted are described as rare, so they are unlikely to explain most cases of limited response to semaglutide.
References
- Nature Medicine. Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide. 2026.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.